News Summary

• The U.S. Food and Drug Administration has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor.
• The NDA is supported by data from the global, multicenter, single-arm, open-label, Phase 1/2 study, BGB-11417-201.
• BeOne will present the full results for the first time at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, in Orlando, Florida.